Pasithea Therapeutics Corp (KTTA)

$0.72 +0.01 (0.70%)
Market Cap 5.34M
Revenue (ttm) 0.00
Net Income (ttm) -13.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 59,700
Avg Vol 117,688
Day's Range N/A - N/A
Shares Out 7.44M
Stochastic %K 79%
Beta 0.26
Analysts Strong Buy
Price Target $2.00

Company Profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, inclu...

Industry: Biotechnology
Sector: Healthcare
Phone: 786 977 3380
Address:
1111 Lincoln Road, Suite 500, Miami Beach, United States
Qriusgman
Qriusgman Aug. 19 at 11:23 PM
$KTTA One last breath...
0 · Reply
d_risk
d_risk Aug. 16 at 10:45 PM
$KTTA - Pasithea Therapeutics Corp. - 10Q - Updated Risk Factors KTTA warns that failure to meet Nasdaq listing requirements could lead to delisting of its common stock and/or public warrants. #Biotechnology #MarketCompliance #StockDelisting #RegulatoryRisk #NasdaqListing 🟢 Added 🟠 Removed https://d-risk.ai/KTTA/10-Q/2025-08-14
0 · Reply
OPTIONTURD
OPTIONTURD Aug. 9 at 1:53 PM
$KTTA The board of directors want to dilute the price further by increasing stock shares and doing a reverse split. I just voted against it.
0 · Reply
Fib7867
Fib7867 Aug. 7 at 3:40 AM
#myKTTAanalysis $KTTA #ThursdayZ
0 · Reply
Kidpicasso
Kidpicasso Aug. 5 at 7:46 PM
$KTTA
0 · Reply
shawky1
shawky1 Aug. 4 at 10:42 AM
$KTTA +1
0 · Reply
XtremeBullz
XtremeBullz Aug. 4 at 9:35 AM
$KLTO $KTTA $BEAM $HOLO ,,
0 · Reply
Jeasie
Jeasie Jul. 31 at 4:38 PM
$KTTA Pas - 004 showing target engagement in phase 1 Watch for rerate
0 · Reply
Jeasie
Jeasie Jul. 31 at 12:57 PM
$KTTA
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 31 at 11:54 AM
$KTTA yet another target hit with huge gains. We sent alert 3 days ago. Follow for more.
0 · Reply
Latest News on KTTA
Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Jul 31, 2025, 7:01 AM EDT - 23 days ago

Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Jun 11, 2025, 7:02 AM EDT - 2 months ago

Pasithea Therapeutics Appoints Expert in ETS2-driven Inflammatory Disease to Scientific Advisory Board

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Jun 2, 2025, 8:02 AM EDT - 2 months ago

Pasithea Therapeutics Presents Updated Interim Data from Ongoing Phase 1 Study of PAS-004 at the ASCO Annual Meeting 2025

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

May 20, 2025, 7:01 AM EDT - 3 months ago

Pasithea Therapeutics Announces Preclinical Data that Shows PAS-004 Inhibits ETS2 Signaling, a Key Driver of Inflammation in IBD and Other Large Addressable Market Diseases

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

May 14, 2025, 7:02 AM EDT - 3 months ago

Pasithea Therapeutics Announces Initiation of Phase 1/1B Study of PAS-004 in Adult NF1 Patients and Activation of First Clinical Trial Site

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

May 7, 2025, 5:00 PM EDT - 3 months ago

Pasithea Therapeutics Announces Closing of $5 Million Public Offering

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

May 6, 2025, 11:10 AM EDT - 3 months ago

Pasithea Therapeutics Announces Pricing of $5 Million Public Offering

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

May 6, 2025, 9:29 AM EDT - 3 months ago

Pasithea Therapeutics Drug Shows Tumor Reduction In Pancreatic Cancer, Strong Early Trial Results

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

May 6, 2025, 7:03 AM EDT - 3 months ago

Pasithea Therapeutics Reports Positive Pharmacodynamic Results Demonstrating Robust Target Engagement from its Ongoing Phase 1 Clinical Trial of PAS-004

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Apr 29, 2025, 7:02 AM EDT - 4 months ago

Pasithea Therapeutics Announces Completion of Enrollment and Initial Dosing of Patients in Cohort 6 from its Phase 1 Trial of PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Apr 24, 2025, 7:02 AM EDT - 4 months ago

Pasithea Therapeutics to Present Updated Data from Ongoing Phase 1 Trial of PAS-004 in Advanced Cancer Patients at the 2025 ASCO Annual Meeting

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Apr 10, 2025, 7:02 AM EDT - 4 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its Ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Feb 5, 2025, 6:59 AM EST - 7 months ago

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Jan 14, 2025, 8:02 AM EST - 7 months ago

Pasithea Therapeutics Announces Opening of European Clinical Trial Sites and Completes Initial Dosing of Cohort 4

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Sep 26, 2024, 6:44 PM EDT - 11 months ago

Pasithea Therapeutics Announces $5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Sep 26, 2024, 8:56 AM EDT - 11 months ago

Why Is Pasithea Therapeutics Stock Surging On Thursday?

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Sep 26, 2024, 7:02 AM EDT - 11 months ago

Pasithea Therapeutics Announces Positive Initial Safety, Tolerability, Pharmacokinetic (PK), and Preliminary Efficacy Data from its Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Sep 9, 2024, 8:01 AM EDT - 1 year ago

Pasithea Therapeutics Announces Successful Completion of PAS-004 Chronic Toxicity Studies

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Sep 3, 2024, 8:02 AM EDT - 1 year ago

Pasithea Therapeutics Announces Appointment of Dr. Rebecca Brown to its Scientific Advisory Board

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 28, 2024, 9:11 AM EDT - 1 year ago

Pasithea Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

May 28, 2024, 6:59 AM EDT - 1 year ago

Pasithea Therapeutics to Present New Preclinical Data Showing PAS-004 Strongly Inhibits NRAS Cancer Cell Lines and Demonstrates Superior Activity in Xenograft Studies at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Apr 29, 2024, 7:59 AM EDT - 1 year ago

Pasithea Therapeutics Announces PAS-004 Abstract Accepted for Poster Presentation at 2024 ASCO Annual Meeting

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Apr 24, 2024, 7:59 AM EDT - 1 year ago

Pasithea Therapeutics Announces the First Cohort has Completed the Initial Dosing in its Phase 1 Trial Evaluating PAS-004 in RAS, NF1 and RAF Mutated Cancers

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Feb 13, 2024, 7:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for its Phase 1 Trial of PAS-004

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Jan 8, 2024, 7:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Jan 2, 2024, 8:35 AM EST - 1 year ago

Pasithea Therapeutics Announces FDA Acceptance of IND Application to Evaluate PAS-004 in Advanced Cancer Patients

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Dec 28, 2023, 5:00 PM EST - 1 year ago

Pasithea Therapeutics Announces Adjournment of Reconvened Meeting of Stockholders to December 29, 2023

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Dec 19, 2023, 5:19 PM EST - 1 year ago

Pasithea Therapeutics Announces Results from 2023 Annual Meeting

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Dec 11, 2023, 8:01 AM EST - 1 year ago

Pasithea Therapeutics Announces Positive In Vivo Preclinical Efficacy Data for PAS-004 from NRAS Mutation Cancer Xenograft Models

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Nov 29, 2023, 4:27 PM EST - 1 year ago

Pasithea Therapeutics Announces Adjournment of 2023 Annual Meeting of Stockholders

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Nov 29, 2023, 7:59 AM EST - 1 year ago

Pasithea Therapeutics Announces Outcome of Pre-IND Meeting with FDA for PAS-004 Clinical Development

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Nov 9, 2023, 7:59 AM EST - 1 year ago

Pasithea Therapeutics Selects PAS-003 Lead Development Candidate, a Humanized Monoclonal Antibody that Targets α5β1 Integrin for the Treatment of both Sporadic and Familial ALS

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Sep 14, 2023, 8:30 AM EDT - 2 years ago

Pasithea Therapeutics Corp. Announces Final Results of Tender Offer

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Sep 7, 2023, 4:14 PM EDT - 2 years ago

Pasithea Therapeutics to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Aug 1, 2023, 7:59 AM EDT - 2 years ago

Pasithea Therapeutics publishes study in Proceedings of the National Academy of Sciences (PNAS) that shows an increase in α5 integrin expression in ALS human and mouse brain tissue, and further demonstrates targeting α5 integrin results in improved surviv

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Jul 20, 2023, 8:43 AM EDT - 2 years ago

Pasithea Therapeutics Announces Intention to Commence a $4.0 Million Tender Offer for its Common Stock at Price of $0.70 per Share in Cash

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Jul 20, 2023, 8:40 AM EDT - 2 years ago

Pasithea Therapeutics Special Committee Rejects Unsolicited Bid from Lucy Scientific Discovery, Inc.

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Jun 30, 2023, 9:28 AM EDT - 2 years ago

Pasithea Therapeutics Confirms Previous Creation of Independent Special Committee of its Board of Directors

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Jun 6, 2023, 4:30 PM EDT - 2 years ago

Pasithea Therapeutics Confirms Receipt of Unsolicited Proposal from Lucy Scientific Discovery Inc.

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

Jun 1, 2023, 7:57 AM EDT - 2 years ago

Pasithea Therapeutics Abstract Accepted for Poster Presentation at 2023 Neurofibromatosis Conference

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

May 3, 2023, 8:26 AM EDT - 2 years ago

Pasithea Therapeutics to Participate in EF Hutton Inaugural Global Conference

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P.

Feb 23, 2023, 8:00 AM EST - 2 years ago

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Deliver Dr. Kenneth P.

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

Feb 16, 2023, 7:30 AM EST - 2 years ago

Pasithea Therapeutics Chairman, Prof. Lawrence Steinman to Receive Pioneer in Medicine Award

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

Jan 18, 2023, 8:00 AM EST - 2 years ago

Pasithea Therapeutics Signs CMC Development and Manufacturing Agreement for the Production of PAS-004

Majority of Stockholders Support Pasithea Directors at Special Meeting

Dec 14, 2022, 5:18 PM EST - 2 years ago

Majority of Stockholders Support Pasithea Directors at Special Meeting

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

Dec 12, 2022, 7:00 AM EST - 2 years ago

Pasithea Therapeutics Announces Comprehensive Settlement Agreement with the Camac Group

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Dec 7, 2022, 4:00 PM EST - 2 years ago

Investor Group Recommends Stockholders Vote the WHITE Proxy Card for Boardroom Change at Pasithea Therapeutics

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

Dec 6, 2022, 8:00 AM EST - 2 years ago

Pasithea Therapeutics to Present at Annual Meeting of the Antibody Society Conference

Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time

Nov 28, 2022, 7:05 PM EST - 2 years ago

Pasithea Therapeutics Postpones Special Meeting until December 9, 2022 at 9:00 AM Eastern Time

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

Oct 17, 2022, 8:00 AM EDT - 3 years ago

Pasithea Therapeutics to Present Tolerizing Vaccine Program Results at Immunotherapy 2022 International Course and Symposium

Qriusgman
Qriusgman Aug. 19 at 11:23 PM
$KTTA One last breath...
0 · Reply
d_risk
d_risk Aug. 16 at 10:45 PM
$KTTA - Pasithea Therapeutics Corp. - 10Q - Updated Risk Factors KTTA warns that failure to meet Nasdaq listing requirements could lead to delisting of its common stock and/or public warrants. #Biotechnology #MarketCompliance #StockDelisting #RegulatoryRisk #NasdaqListing 🟢 Added 🟠 Removed https://d-risk.ai/KTTA/10-Q/2025-08-14
0 · Reply
OPTIONTURD
OPTIONTURD Aug. 9 at 1:53 PM
$KTTA The board of directors want to dilute the price further by increasing stock shares and doing a reverse split. I just voted against it.
0 · Reply
Fib7867
Fib7867 Aug. 7 at 3:40 AM
#myKTTAanalysis $KTTA #ThursdayZ
0 · Reply
Kidpicasso
Kidpicasso Aug. 5 at 7:46 PM
$KTTA
0 · Reply
shawky1
shawky1 Aug. 4 at 10:42 AM
$KTTA +1
0 · Reply
XtremeBullz
XtremeBullz Aug. 4 at 9:35 AM
$KLTO $KTTA $BEAM $HOLO ,,
0 · Reply
Jeasie
Jeasie Jul. 31 at 4:38 PM
$KTTA Pas - 004 showing target engagement in phase 1 Watch for rerate
0 · Reply
Jeasie
Jeasie Jul. 31 at 12:57 PM
$KTTA
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 31 at 11:54 AM
$KTTA yet another target hit with huge gains. We sent alert 3 days ago. Follow for more.
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 31 at 11:08 AM
$KTTA Pharmacodynamic data indicates up to 91% pERK inhibition, reflecting robust target engagement. Preliminary activity included stable disease and modest tumor reductions in solid tumor patients
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 31 at 11:06 AM
$KTTA pt $1+
0 · Reply
BigSqueezeComing
BigSqueezeComing Jul. 31 at 11:06 AM
$KTTA Pasithea Therapeutics Completes Enrollment and Initial Dosing of First Cohort from its Phase 1/1b Clinical Trial of PAS-004 in Adult NF1 Patients By Pasithea | July 31, 2025, 7:01 AM
0 · Reply
Pharma_Stock_Calls
Pharma_Stock_Calls Jul. 28 at 2:45 PM
$SPY $KTTA ✅ 💊 $KTTA Entry: $0.7265 → Target: $0.81
0 · Reply
BioTechHealthX
BioTechHealthX Jul. 20 at 5:07 PM
$KTTA Backed by institutional money and a best-in-class drug candidate, Pasithea may be poised for liftoff. Explore the bullish case now. https://biotechhealthx.com/biotech-news/pasithea-therapeutics-ktta-just-raised-5-million-is-this-the-spark-it-needed/
0 · Reply
JustinDTLV
JustinDTLV Jul. 14 at 11:21 PM
$KTTA Nice AH volume compared to the past few trading days.
0 · Reply
encostock
encostock Jul. 12 at 10:01 AM
$KTTA
0 · Reply
StockFlips
StockFlips Jul. 11 at 12:56 PM
$KTTA starter in
2 · Reply
WallStVisions
WallStVisions Jul. 7 at 5:36 AM
$ONFO $KTTA Keep these on the radar
0 · Reply
JustinDTLV
JustinDTLV Jul. 4 at 2:48 AM
$KTTA received a notice from Nasdaq for not meeting the $1.00 minimum bid price requirement. They have until December 22 (180 days) to regain compliance. https://www.sec.gov/Archives/edgar/data/1841330/000121390025059004/ea0246913-8k_pasithea.htm
0 · Reply
Adubstradesmini
Adubstradesmini Jul. 3 at 10:56 PM
$KTTA
0 · Reply
Fib7867
Fib7867 Jul. 2 at 10:03 PM
#myKTTAanalysis $KTTA
0 · Reply